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1 Abstract
This two-part review examines how automation has contributed to different aspects of discovery in the
chemical sciences. In this second part, we reflect on a selection of exemplary studies. It is increasingly
important to articulate what the role of automation and computation has been in the scientific process and
how that has or has not accelerated discovery. One can argue that even the best automated systems have
yet to “discover” despite being incredibly useful as laboratory assistants. We must carefully consider how
they have been and can be applied to future problems of chemical discovery in order to effectively design
and interact with future autonomous platforms.
The majority of this article defines a large set of open research directions, including improving our ability
to work with complex data, build empirical models, automate both physical and computational experiments
for validation, select experiments, and evaluate whether we are making progress toward the ultimate goal
of autonomous discovery. Addressing these practical and methodological challenges will greatly advance the
extent to which autonomous systems can make meaningful discoveries.
2 Reflection on case studies
In 2009, King et al. proposed a hypothetical, independent robot scientist that "automatically originates
hypotheses to explain observations, devises experiments to test these hypotheses, physically runs the exper-
iments by using laboratory robotics, interprets the results, and then repeats the cycle" [1]. To what extent
have we closed the gap toward each of these workflow components, and what challenges remain?
The case studies in Part 1 illustrate many examples of the progress that has been made toward achieving
machine autonomy in discovery. Several studies in particular, summarized in Table 1, represent what we
consider to be exemplars of different discovery paradigms [2–15]. These include the successful execution of
experimental and computational workflows as well as the successful implementation of automated exper-
imental selection and belief revision. There are a great number of studies (some of which are described
in part one) that follow the paradigm of (a) train a surrogate QSAR/QSPR model on existing data, (b)
computationally design a molecule or material to optimize predicted performance, and (c) manually validate
a few compounds. The table intentionally underrepresents such studies, as we believe iterative validation to
be a distinguishing feature of autonomous workflows compared to “merely” automated calculations.
We encourage the reader to reflect on these case studies through the lens of the questions we pro-
posed for assessing autonomous discovery: (i) How broadly is the goal defined? (ii) How constrained is
the search/design space? (iii) How are experiments for validation/feedback selected? (iv) How superior to
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a brute force search is navigation of the design space? (v) How are experiments for validation/feedback
performed? (vi) How are results organized and interpreted? (vii) Does the discovery outcome contribute to
broader scientific knowledge?
The goals of discovery are defined narrowly in most studies. We are not able to request that a platform
identify a good therapeutic, come up with an interesting material, uncover a new reaction, or propose an
interesting model. Instead, in most studies described to date, an expert defines a specific scalar performance
objective that an algorithm tries to optimize. Out of the examples in Table 1, Kangas et al. has the highest-
level goals: in one of their active learning evaluations, the goal could be described as finding strong activity
for any of the 20,000 compounds against any of the 177 assays. While Adam attempts to find relationships
between genes and the enzymes they encode (discover a causal model), it does so from a very small pool of
hypotheses for the sake of compatibility with existing deletion mutants for a single yeast strain.
The search spaces used in these studies vary widely in terms of the constraints that are imposed upon
them. Some are restricted out of necessity to ensure validation is automatable (e.g., Eve, Adam, Desai
et al., ARES) or convenient (e.g., Weber et al., Fang et al.). Others constrain the search space to a greater
degree than automated validation requires. This includes reductions of 1) dimensionality, by holding process
parameters constant (e.g., Reizman et al., Ada), or 2) the size of discrete candidate spaces (e.g., Gómez-
Bombarelli et al., Thornton et al., Janet et al.). Computational studies that minimize constraints on their
search (e.g., RMG, Segler et al.) do so under the assumption that the results of validation (e.g., simulation
results, predictions from surrogate models) will be accurate across the full design space.
In all cases, human operators have implicitly or explicitly assumed that a good solution can be found in
these restricted spaces. The extent to which domain expertise or prior knowledge is needed to establish the
design space also varies. Molecular or materials design in relatively unbounded search spaces (e.g., Segler et
al.) requires the least human input. Fixed candidate libraries that are small (e.g., Weber et al., Desai et al.)
or derived from an expert-defined focused enumeration (e.g., RMG, Gómez-Bombarelli et al., Janet et al.)
require significant application-specific domain knowledge; larger fixed candidate libraries may be application-
agnostic (e.g., diverse screening libraries in Eve, Fang et al., Thornton et al.). Limiting process parameters
(e.g., Reizman et al., ARES, Ada) require more general knowledge about typical parameter ranges where
optima may lie.
The third question regarding experiment selection is one where the field has excelled. There are many
frameworks for quantifying the value of an experiment in model-guided experimental design, both when
optimizing for performance and when optimizing for information [17]. However, active learning with formal
consideration of uncertainty from either a frequentist perspective [18] (e.g., Eve, Reizman et al.) or a Bayesian
perspective [19, 20] (e.g., Ada) is less common than with ad hoc definitions of experimental diversity meant
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to encourage exploration (e.g., Desai et al., Kangas et al.). Both are less common than greedy selection
criteria (e.g., ARES, RMG, Gómez-Bombarelli et al., Thornton et al.). Model-free experiment selection,
including the use of genetic algorithms (e.g., Weber et al., Janet et al.), is also quite prevalent but requires
some additional overhead from domain experts to determine allowable mutations within the design space.
When validation is not automated (e.g., Fang et al. or Gómez-Bombarelli et al.’s experimental follow-up), the
selection of experiments is best described as pseudo-greedy, where the top predicted candidates are manually
evaluated for practical factors like synthesizability.
The magnitude of the benefit of computer-assisted experiment selection is a function of the size of the
design space and, when applicable, the initialization required prior to the start of the iterative phase. In many
cases, a brute force exploration of the design space is not prohibitively expensive (e.g., Eve, Adam, Desai
et al., Janet et al.), although this is harder to quantify when some of the design variables are continuous (e.g.,
Reizman et al., ARES, Ada). Other design spaces are infinite or virtually infinite (e.g., RMG, Segler et al.),
which makes the notion of a brute force search ill-defined. Regardless of whether the full design space can
be screened, we can still achieve a reduction in the number of experiments required to find high-performing
candidates, perhaps by a modest factor of 2-10 (e.g., Eve, Desai et al., Gómez-Bombarelli et al., Janet et al.)
or even by 2-3 orders of magnitude (e.g., Weber et al., Kangas et al., Thornton et al.). It’s possible that the
experimental efficiency of some of these studies could be improved by reducing the number of experiments
needed to initialize the workflow (e.g., Eve, Gómez-Bombarelli et al.).
The manner in which experiments for validation are performed depends on the nature of the design space
and, of course, whether experiments are physical or computational. Examples where validation is automated
are intentionally overrepresented in this review; there are many more examples of partially-autonomous
discovery in which models prioritize experiments that are manually performed (e.g., similar to Weber et
al., Fang et al.). There are also cases where almost all aspects of experimentation are automated but a
few manual operations remain (e.g., transferring well plates for Adam). In computational workflows, one
can often construct pipelines to automate calculations (e.g., RMG, Gómez-Bombarelli et al., Segler et al.,
Thornton et al., Janet et al.). In experimental workflows, one can programmatically set process conditions
with tailor-made platforms (e.g., Desai et al., ARES, Ada) or robotically perform assays using in-stock
compounds (e.g., Eve, Adam) or ones synthesized on-demand (e.g., Desai et al.). Pool-based active learning
strategies lend themselves to retrospective validation, where an “experiment” simply reveals a previous result
not known to the algorithm (e.g., Kangas et al.); this is trivially automated and thus attractive for method
development. Note that in the workflow schematic for Kangas et al. in Table 1, we illustrate the revelation
of PubChem measurements as experiments.
In iterative workflows, automating the organization and interpretation of results is a practical step toward
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automating the subsequent selection of experiments. When workflows only proceed through a few iterations
of batched experiments, humans may remain in the loop to simplify the logistics of organizing results and
initializing each round (e.g., Gómez-Bombarelli et al., Thornton et al.), but nothing fundamentally prevents
this step from being automated. When many iterations are required or expected, it behooves us to ensure
that the results of experiments can be directly interpreted; otherwise, tens (e.g., Desai et al., Reizman
et al., Segler et al., Janet et al., Ada) or hundreds (e.g., Eve, ARES, Kangas et al.) of interventions by
human operators would be required. This can be the case when iterative experimental design is used with
manual experimentation and analysis (e.g., the 20 iterations of a genetic algorithm conducted manually by
Weber et al.). In non-iterative workflows with manual validation (e.g., Fang et al.), there is little benefit
to automating the interpretation of new data. Relative to automating experiments and data acquisition,
automating the interpretation thereof is rarely an obstacle to autonomy. Exceptions to this include cases
where novel physical matter (a molecule or material) is synthesized and characterized (e.g., case studies
in Part 1 related to experimental reaction discovery), where further advances in computer-aided structural
elucidation (CASE) [21] are needed.
Our final question when assessing autonomy is whether the discovery outcome contributes to broader
scientific knowledge. In Table 1, with the exception of Adam and RMG, we have focused on the discovery of
physical matter or processes rather than models. The primary outcome of these discovery campaigns is the
identification of a molecule, material, or set of process conditions that achieves or optimizes a human-defined
performance objective. Workflows with model-based experimental designs (e.g., all but Weber et al. and
Janet et al., who use genetic algorithms) have the secondary outcome of a surrogate model, which may
or may not lend itself to interpretation. However, the point of this question is whether the contribution
to broader scientific knowledge came directly from the autonomous platform, not through an ex post facto
analysis by domain experts. These discoveries generally require manual interpretation, again excepting
Adam, RMG, and similar platforms where what is discovered is part of a causal model.
Our first and last questions represent lofty goals in autonomous discovery: we specify high-level goals
and receive human-interpretable, generalized conclusions beyond the identification of a molecule, material,
device, process, or black box model. However, we have made tremendous progress in offloading both the
manual and mental burden of navigating design spaces through computational experimental design and
automated validation. We often impose constraints on design spaces to avoid unproductive exploration and
focus the search on what we believe to be plausible candidates. To widen a design space requires that
experiments remain automatable–less of a challenge for computational experiments than for physical ones–
but may decrease the need for subject matter expertise and may increase the odds that the platform identifies
an unexpected or superior result. Well-established frameworks of active learning and Bayesian optimization
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have served us well for experimental selection, while new techniques in deep generative modeling have opened
up opportunities for exploring virtually-infinite design spaces.
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initial design selected experiment data belief/model existing data
algorithmic
expert-defined
physical
computational
model-free design
model-based design
update initialize
Reference Discovery Initialization Design space Data generation Notes Workflow
Eve [2]
bioactive,
selective
molecules
4,800 random
compounds from
design space
fixed library of
14,400 compounds
automated
measurement of
yeast growth
curves
compound screening from a
fixed library with an active
search
· · · · ·
Adam [3] gene-enzymerelationships
random
experiment
15 open reading
frame deletions
automated
auxotrophy
experiments
narrow hypothesis space,
but nearly-closed-loop
experimentation
· · · · ·
Weber
et al. [4]
thrombin
inhibitors
20 random
compounds
virtual
10 × 10 × 40 × 40
compound library
manual synthesis
and inhibition
assay
iterative optimization using
a genetic algorithm; design
space defined by
4-component Ugi reaction to
ensure synthesizability
· · · · ·
Desai et al.
[5] kinase inhibitors random compound
27 × 10 candidates
in
make-on-demand
library
automated
microfluidic
synthesis and
biological testing
closed-loop synthesis and
biological testing; narrow
chemical design space
· · · · ·
Reizman
et al. [6]
reaction
conditions
algorithmic
D-optimal design
concentration,
temperature, time,
8 catalysts
automated
synthesis and yield
quantitation
closed-loop reaction
optimization through a
screening phase and an
iterative phase
· · · · ·
ARES [7,
16]
carbon
nanotube
growth
conditions
84 expert-defined
experimental
conditions
process conditions
(temperature,
pressures, and gas
compositions)
automated
nanotube growth
and
characterization
complex experimentation;
uses RF model for
regression
· · · · ·
Kangas
et al. [8]
bioactive
compounds
against many
assays
384 random
measurements
from design space
177 assay ×
20,000 compound
interactions
simulated
experiments by
revealing
PubChem
measurements
validation of pool-based
active learning framework
through retrospective
analysis; iterative batches of
384 experiments
· · · · ·
RMG [9]
detailed
gas-phase
kinetic
mechanisms
reaction
conditions,
optionally seeded
by known
mechanism
elementary
reactions following
expert-defined
reaction templates
estimation of
thermodynamic
and kinetic
parameters
iterative addition of
hypothesized elementary
reactions to a kinetic model
based on simulations using
intermediate models
· · · · ·
Fang et al.
[10]
neuroprotective
compounds
activity data from
ChEMBL
in-house library of
28k candidates none
literature-trained QSAR
model applied to
noniterative virtual
screening with manual in
vitro validation
· · · · ·
Gómez-
Bombarelli
et al. [11]
organic
light-emitting
diode molecules
40k random
compounds from
design space
virtual library of
1.6 M enumerated
compounds
DFT calculations
iteratively selected batches
of 40k calculations;
manually validated a small
number of compounds
experimentally
· · · · ·
Segler
et al. [12]
bioactive
compounds
1.4M molecules
from ChEMBL
all of chemical
space
surrogate
QSAR/QSPR
models of activity
iteratively refined
generative LSTM model
(pretrained on ChEMBL) on
active molecules identified
via sampling an initial 100k
+ 8 rounds × 10k molecules
· · · · ·
Thornton
et al. [13]
hydrogen
storage
materials
200 human-chosen
subset and 200
random subset of
search space
850k structures
(Materials
Genome)
grand canonical
Monte Carlo
simulations
few rounds of greedy
optimization with batches
of 1000 using surrogate
QSPR model
· · · · ·
Janet et al.
[14]
spin-state
splitting
inorganic
complexes
random complexes
from design space
708 ligand
combinations × 8
transition metals
ANN surrogate
model prediction
used genetic algorithm and
computational evaluation
for iterative optimization;
relies on ANN pretrained on
2690 DFT calculations
· · · · ·
Ada [15]
organic hole
transport
materials
algorithmic dopant ratio andannealing time
automated
synthesis and
analysis of thin
film
complex experimentation
successfully automated;
simple design space
· · · · ·
Table 1: Selected examples of discovery accelerated by automation or computer assistance. The stages of
the discovery workflow employed by each are shown as red arrows corresponding to the schematic above.
Workflows may begin either with an initial set of experiments to run or by initializing a model with existing
(external) data. Algorithmic initial designs include the selection of random experiments from the design
space.
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3 Challenges and trends
The capabilities required for autonomous discovery are coming together rapidly. This section emphasizes
what we see as key remaining challenges associated with working with complex data, automating validation
and feedback, selecting experiments, and evaluation.
3.1 Working with complex data
The discovery of complex phenomena requires a tight connection between knowledge and data [22]. A 1991
article laments the “growing gap between data generation and data understanding” and the great potential
for knowledge discovery from databases [23]. While we continue to generate new data at an increasing rate,
we have also dramatically improved our ability to make sense of complex datasets through new algorithms
and advances in computing power.
We intentionally use “complex data” rather than “big data”–the latter generally refers only to the size or
volume of data, and not its content. Here, we mean “complex data” when it would be difficult or impossible
for a human to identify the same relationships or conclusions as an algorithm. This may be due to the size
of the dataset (e.g., millions of bioactivity measurements), the lack of structure (e.g., journal articles), or
the dimensionality (e.g., a regression of multidimensional process parameters).
Complex datasets come in many forms and have inspired an array of different algorithms for making
sense of them (and leveraging them for discovery). Unstructured data can be mined and converted into
structured data [24, 25] or directly analyzed as text, e.g. to develop hypotheses about new functional
materials [26]. Empirical models can be generated and used to draw inferences about factors that influence
complex chemical reactivity [27–30]. Virtually any dataset of (input, output) pairs describing a performance
metric of a molecule, material, or process can serve as the basis for supervised learning of a surrogate model.
Likewise, unsupervised techniques can be used to infer the structure of complex datasets [31–33] and form
the basis of deep generative models that propose new physical matter [34, 35].
3.1.1 Creating and maintaining datasets
Many studies don’t develop substantially novel methods, but instead take advantage of new data resources.
This is facilitated by the increasing availability of public databases. The PubChem database, maintained by
the NIH and currently the largest repository of open-access chemical information [36], has been leveraged
by many studies for ligand-based drug discovery proofs and thus is a particularly noteworthy example of the
value inherent in these curation efforts. Curation efforts spearheaded by government organizations as well as
those led by individual research groups can both be enormously impactful, whether through amalgamation
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of large existing datasets (a greater strength of the broad collaborations) or the accumulation of high-quality,
well-curated data (which efforts by individual research groups tend may be better suited for).
Table 2 provides a list of some popular databases used for tasks related to chemical discovery. Additional
databases related to materials science can be found in refs. 37 and 38. Some related to drug discovery are
contained in refs. 39 and 40. Additional publications compare commercial screening libraries that can be
useful in experimental or computational workflows [41, 42].
Table 2: Overview of some databases used to facilitate discovery in the chemical sciences. API: application
programming interface
Chemical structures
Name Description Size (approx.) Availability
ZINC [43, 44] commercially-available compounds 35 M Open
ChemSpider [45] structures and misc. data 67 M API
SureChEMBL [46] structures from ChEMBL 1.9 M Open
Super Natural II [47] natural product structures 325 k Open
SAVI [48] enumerated synthetically-accessible structures and their building
blocks
283 M Open
eMolecules [49] commercially-available chemicals and prices 5.9 M Commercial
MolPort [50] in-stock chemicals and prices 7 M On Request
REAL (Enamine) [51] enumerated synthetically-accessible structures 11 B Open
Chemspace [52] in-stock chemicals and prices 1 M On Request
GDB-11, GDB-13,
GDB-17 [53–55]
exhaustively enumerated chemical structures 26.4 M; 970 M;
166 B
Open
SCUBIDOO [56] enumerated synthetically-accessible structures > 10 M Open
CHIPMUNK [57] enumerated synthetically-accessible structures 95 M Open
Biological data
Name Description Size Availability
PubChem [36] compounds and properties, emphasis on bioassay results 96 M Open
ChEMBL [58, 59] compounds and bioactivity measurements 1.9 M Open
ChEBI [60] compounds and biological relevance 56 k Open
PDB [61] biological macromolecular structures 150 k Open
PDBBind [62] protein binding affinity 20 k Open
ProTherm [63] thermodynamic data for proteins 10 k Open
LINCS [64] cellular interactions and perturbations varies Open
SKEMPI [65] energetics of mutant protein interactions 7 k Open
xMoDEL [66] MD trajectories of proteins 1700 Open
GenBank [67] species’ nucleotide sequences 400 k Open
DrugBank [68] drug compounds, associated chemical properties, and pharmacological
information
13 k Open
BindingDB [69] compounds and binding measurements 750 k; 1.7 M Open
CDD [70] collaborative drug discovery database for neglected tropical diseases > 100 datasets Registration
ToxCast [71, 72] compounds and cellular responses > 4500 Open
Tox21 [73, 74] compounds and multiple bioassays 14k Open
Chemical reactions
Name Description Size Availability
USPTO [75] chemical reactions (patent literature) 3.3 M Open
Pistachio [76] chemical reactions (patent literature) 8.4 M Commercial
Reaxys [77] chemical reactions >10 M Commercial
CASREACT [78] chemical reactions >10 M Commercial
SPRESI [79] chemical reactions 4.3 M Commercial
Organic Reactions [80] chemical reactions 250 k Commercial
EAWAG-BBD [81] biocatalysis and biodegradation pathways 219 Open
NIST Chemical Kinet-
ics [82]
gas-phase chemical reactions 38 k Open
NMRShiftDB [83] measured NMR spectra 52 k Open
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Molecular properties
Name Description Size Availability
QM7/QM7b [84, 85] electronic properties (DFT) 7200 Open
QM9 [86] electronic properties (DFT) 134 k Open
QM8 [87] spectra and excited state properties 22 k Open
FreeSolv [88] aqueous solvatio energies 642 Open
NIST Chemistry Web-
Book [89]
miscellaneous molecular properties varies Open
Materials
Name Description Size Availability
PoLyInfo [90] polymer properties 400k Open
COD [91–93] crystal structures of organic, inorganic, metal-organics compounds
and minerals
410k Open
CoRE MOF [94] properties of metal-organic frameworks 5k Open
hMOF [95] hypothetical metal-organic frameworks 140k Open
CSD [96] crystal structures 1 M API
ICSD [97] crystal structure data for inorganic compounds 180k Commercial
NOMAD [98] total energy calculations 50 M Open
AFLOW [99, 100] material compounds; calculated properties 2.1M; 282M Open
OQMD [101] total energy calculations 560 k Open
Materials Project [102] inorganic compounds and computed properties 87 k API
Computational Mate-
rials Repository [103,
104]
inorganic compounds and computed properties varies Open
Pearson’s [105] crystal structures 319 k Commercial
HOPV [106] experimental photovoltaic data from literature, QM calculations 350 k Open
Journal articles
Name Description Size Availability
Crossref [107] journal article metadata 107 M Open
PubMed [108] biomedical citations 29 M Open
arXiv [109] arXiv articles (from many domains) 1.6 M Open
Wiley [110] full articles millions API
Elsevier [111] full articles millions API
Several factors have contributed to the greater wealth and accessibility of chemical databases that can
be used to facilitate discovery. The first of these has to do with hardware: automated experimentation,
especially that which is high-throughput in nature, has allowed us to generate data at a faster pace. Second,
the successes of computational tools at leveraging these large quantities of data has created a self-catalyzing
phenomenon: as the capabilities of tools are more frequently and widely demonstrated, the incentive to
collect and curate large datasets that can be used by these tools has grown.
Challenge: Establish open access databases with standardized data representations
Time invested in the creation of open databases of molecules, materials, and processes can have an outsized
impact on discovery efforts that are able to make use of that data for supervised learning or screening.
Creating and maintaining these databases is not without its challenges. There’s much to be done to
capture and open-source the data generated by the scientific community. For cases where data must be
protected by intellectual property agreements, we need software that can facilitate sharing between collab-
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orators and guarantee privacy as needed [112, 113]. Even standardizing representations can be challenging,
particularly for polymeric materials with stochastic structures and process-dependent attributes [114].
Government funding agencies in the EU and US are starting to prioritize accessibility of research results
to the broader community [115]. Further evolution of the open data policies will accelerate discovery through
broader analysis of data (crowdsourcing discovery [116–118]) and amalgamation of data for the purposes of
machine learning. Best practices among experimentalists must begin to include the storage of experimental
details and results in searchable, electronic repositories.
The data that exists in the literature that remains to be tapped by the curation efforts described above
is vast. To access it, scientific researchers are gaining increasing interest in adapting information extraction
techniques for use in chemistry [119–124]. Information extraction and natural language processing bring
structure to unstructured data, e.g., published literature that presents information in text form. Methods
have evolved from identifying co-occurrences of specifics words [125] to the formalization of domain-specific
ontologies [126], learned word embeddings [26], knowledge graphs and databases [122], and causal models [25].
Learning from unstructured data presents additional challenges in terms of data set preparation and problem
formulation, and is significantly less popular than working with pre-tabulated databases. Nevertheless,
building knowledge graphs of chemical topics may eventually let us perform higher level reasoning [127] to
identify and generalize from novel trends.
Challenge: Address the inconsistent quality of existing data
Existing datasets may not contain all of the information needed for a given prediction task (i.e., the input
is underspecified or the schema is missing a metric of interest). Even when the right fields are present,
there may be missing or misentered data from automated information extraction pipelines or manual
entry.
As Williams et al. point out, data curation (which involves evaluating the accuracy of data stored in
repositories) before the data is used to create a model or otherwise draw conclusions is very important:
data submitted to the PDB is independently validated before it is added to the database, whereas data
added to PubChem undergoes no prerequisite curation or validation [128]. Lack of curation results in many
problems associated with missing and/or misentered data. These issues plague databases including the PDB
(misassigned electron density) and Reaxys (missing data). As analytical technology continues to improve,
one can further ask how much we should bother relying on old data in lieu of generating new data that we
trust more.
Existing database curation policies must account for the potential for error propagation and incorporate
standardization procedures that can correct for errors when they arise [129, 130], for example by using
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ProsaII [131] to evaluate sequence-structure compatibility of PDB entries and identify errors [132]. While
the type of crowdsourcing error correction exemplified by Venclovas et al. can be helpful, we argue that it
shouldn’t be relied upon [132]; curators should preemptively establish policies to help identify, control, and
prevent errors.
3.1.2 Building empirical models
Various statistical methods have been used for model-building for many years. Some of the most dramatic
improvements to statistical learning have been in the area of machine learning. Machine learning is now
the go-to for developing empirical models that describe nonlinear structure-function relationships that es-
timate the properties of new physical matter and serve as surrogate models for expensive calculations or
experiments. These types of empirical models act as a roadmap for many discovery efforts, so improvements
here significantly impact computer-aided discovery, even when the full workflow is not automated. Packages
like scikit-learn, Tensorflow, and Pytorch have lowered the barrier for implementing empirical models, and
chemistry-specific packages like DeepChem [133] and ChemML [134] represent further attempts to streamline
model training and deployment (with mixed success in adoption).
Challenge: Improve representations of molecules and materials
A wide array of strategies for representing molecules and materials for the sake of empirical modeling
have been developed, but certain aspects have yet to be adequately addressed by existing representation
methods. Further, it is difficult to know which representation method will perform best for a given
modeling objective.
In the wake of the 2012 ImageNet competition, in which a convolutional neural network dominated rule-
based systems for image classification [135], there has been a shift in modeling philosophy to avoid human
feature engineering, e.g., describing molecules by small numbers of expert descriptors, and instead learn
suitable representations [136]. This is in part enabled by new network architectures, such as message passing
networks particularly suited to embedding molecular structures [137–139]. There is no consensus as to when
the aforementioned deep learning techniques should be applied over “shallower” learning techniques like RFs
or SVMs with fixed representations [140]; which method performs best is task-dependent and determined
empirically [133, 141], although some heuristics, e.g. regarding the fingerprint granularity needed for a
particular materials modeling task, do exist [142]. Use of molecular descriptors may make generalization to
new inputs more predictable [28] but limits the space of relationships able to be described by presupposing
that the descriptors contain all information needed for the prediction task. Further, selecting features for
low-dimensional descriptor-based representations requires expert-level domain knowledge.
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In addition to a better understanding of why different techniques perform well in different settings,
there is a need for the techniques themselves to better capture relevant information about input structures.
Some common representations in empirical QSAR/QSPR modeling are listed in Table 3. However, there
are several types of inputs that current representations are unable to describe adequately. These include
(a) polymers that are stochastically-generated ensembles of specific macromolecular structures, (b) hetero-
geneous materials with periodicity or order at multiple length scales, and (c) “2.5D” small molecules with
defined stereochemistry but flexible 3D conformations. Descriptor-based representations serve as a catch-all,
as they rely on experts to encode input molecules, materials, or structures as numerical objects.
Representation Description
Descriptors Vector of calculated properties
Fingerprints Vector of presence/absence or count of structural features (many types)
Coulomb matrices Matrix of electrostatic interactions between nuclei
Images 2D line drawings of chemical structures
SMILES String defining small molecule connectivity (can be tokenized or
adapted in various ways, e.g., SELFIES, DeepSMILES)
FASTA String for nucleotide or peptide sequences
Graphs 2D representation with connectivity information
Voxels Discretized 3D or 4D representation of molecules
Spatial coordinates 3D representation with explicit coordinates for every atom
Table 3: Representations used in empirical QSAR/QSPR modeling.
Challenge: Improve empirical modeling performance in low-data environments
Empirical modeling approaches must be validated on or extended to situations for which only tens of
examples are available (e.g., a small number of hits from an experimental binding affinity assay).
Defining a meaningful feature representation is especially important when data is limited [143, 144].
Challenging discovery problems may be those for which little performance data is available and validation
is expensive. For empirical models to be useful in these settings, they must be able to make reasonably
accurate predictions with only tens of data points. QSAR/QSPR performance in low-data environments
is understudied, with few papers explicitly examining low-data problems (e.g., fewer than 100 examples)
[145–147]. The amount of data “required” to train a model is dependent on the complexity of the task,
the true (unknown) mathematical relationship between the input representation and output, the size of the
domain over which predictions are made, and the coverage of the training set within that space.
Challenge: Incorporate physical invariance and equivariance properties
By ensuring that models are only sensitive to meaningful differences in input representations, one can
more effectively learn an input-output relationship without requiring data augmentation to also learn
input-input invariance or equivariance.
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One potential way to improve low-data performance and generalization ability is to embed physical
invariance or equivariance properties into models. Consider a model built to predict a physical property
from a molecular structure: molecular embeddings from message passing neural networks are inherently
invariant to atom ordering. In contrast, embeddings calculated from tensor operations on Coulomb matrices
are not invariant. Sequence encoders using a SMILES string representation of a molecule have been shown
to benefit from data augmentation strategies so the model can learn the chemical equivalence of multiple
SMILES strings [148, 149]. There are strong parallels to image recognition tasks, where one may want an
object recognition model to be invariant to translation, rotation, and scale. When using 3D representations of
molecules with explicit atomic coordinates, it is preferable to use embedding architectures that are inherently
rotationally-invariant [150, 151] instead of relying on inefficient preprocessing steps of structure alignment
[29] and/or rotational enumeration [152] for voxel representations, which still may lead to models that do
not obey natural invariance or equivariance laws.
Challenge: Unify and utilize heterogeneous datasets
Vast quantities of unlabeled or labeled data can be used as baseline knowledge for pretraining empirical
models or in a multitask setting when tasks are sufficiently related.
When human researchers approach a discovery task, they do so equipped with an intuition and knowledge
base built by taking courses, reading papers, running experiments, and so on. In computational discovery
workflows with machine learning-based QSAR modeling, algorithms tend to focus only on the exact property
or task and make little use of prior knowledge; only via the input representation, model architecture, and
constraints on the search space is domain-specific knowledge embedded. Models are often trained from
scratch on datasets that contain labeled (molecule, value) pairs.
Such isolated applications of machine learning to QSAR/QSPR modeling can be effective, but there is
a potential benefit to multitask learning or transfer learning when predictions are sufficiently related [153–
157]. Searls argues that drug discovery stands to benefit from integrating different datasets relating to various
aspects of gene and protein functions [158]. As a simple example, one can consider that the prediction of
phenotypes from suppressing specific protein sequences might benefit from knowledge of protein structure,
given the connection between protein sequence→ structure→ function. For some therapeutic targets, there
are dozens of databases known to be relevant that have not been meaningfully integrated [159]. Large-scale
pretraining is a more general technique that can be used to learn an application-agnostic atom- or molecule-
level representation prior to refinement on the actual QSAR task [160–163]. Performance on phenotypic
assays has even been used directly as descriptors for molecules in other property prediction tasks [164], as
has heterogeneous data on drug, protein, and drug-protein interactions [165].
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Challenge: Improve interpretability of machine learning models
Machine learning models are typically applied as black box predictors with some minimal degree of ex
post facto interpretation: analysis of descriptor importance, training example relevance, simplified decision
trees, etc. Extracting explanations consistent with those used by human experts in the scientific literature
requires the structure of the desired explanations to be considered and built into the modeling pipeline.
To the extent that existing autonomous discovery frameworks generate hypotheses that explain observa-
tions and interpret the results of experiments, they rarely do so in a way that is directly intelligible to humans,
limiting the expansion of scientific knowledge that is derived from a campaign. In connection with this, many
of the case studies from Part 1 focus on discoveries that are readily physically observable–identifying a new
molecule that is active against a protein target, or a new material that can be used to improve energy
capture–rather than something more abstract, such as answering a particular scientific question. We can
probe model understanding by enumerating predictions for different inputs, but these are human-defined
experiments to answer human-defined hypotheses (e.g., querying a reaction prediction model with substrates
across a homologous series). Standard approaches to evaluating descriptor importance still require careful
control experiments to ensure that the explanations we extract are not spurious, even if they align with
human intuition [166]. We again refer readers to ref. 167 for a review of QSAR interpretability. Ref. 168
reviews additional aspects of explainable machine learning for scientific discovery.
Many challenges above can be approached by what Rueden et al. call informed machine learning : “the
explicit incorporation of additional knowledge into machine learning models”. The taxonomy they propose
is reproduced in Figure 1. In particular, several points relate to (a) the integration of natural sciences
(laws) and intuition into representations and model architectures and (b) the integration of world knowledge
through pretraining or multitask/transfer learning.
3.2 Automated validation and feedback
Iterating between hypothesis generation and validation can be fundamental to the discovery process. One
often needs to collect new data to refine or prove/disprove hypotheses. Sufficiently advanced automation
can compensate for bad predictions by quickly falsifying hypotheses and identifying false positives [170]
(i.e., being “fast to fail” [171]). The last several decades have brought significant advances in automation of
small-scale screening, synthesis, and characterization, which facilitates validation via physical experiments,
as well as advances in software for faster and more robust computational validation.
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Figure 1: Taxonomy of informed machine learning proposed by Rueden et al. The incorporation of prior
knowledge into machine learning modeling can take a number of forms. Figure reproduced from ref. 169.
3.2.1 Experimental validation
Many of the case studies we present portray great strides in terms of the speed and scale of experimental
validation. High-throughput and parallelized experimentation capabilities have been transformational in
the biological space and increasingly are being imported into the chemistry space [172]. The adoption
of HTE has simplified screening broad design spaces for new information [173–175]. Beyond brute-force
experimentation, there are new types of experiments to accelerate the rate of data generation and hypothesis
validation. These include split-and-pool techniques and other combinatorial methods to study multiple
candidates simultaneously [176–178].
Challenge: Expand the scope of automatable experiments
Whether an iterative discovery problem’s hypotheses can be autonomously validated depends on whether
the requisite experiments are amenable to automation.
If we are optimizing a complex design objective, such as in small molecule drug discovery, we benefit from
having access to a large search space. Many syntheses and assays are compatible with a well-plate format
and are routinely automated (e.g., Adam [3] and Eve [2]). Moving plates, aspirating/dispensing liquid,
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and heating/stirring are all routine tasks for automated platforms. Experiments requiring more complex
operations may still be automatable, but require custom platforms, e.g., for the growth and characterization
of nanotubes by ARES [7] or deposition and characterization of thin films by Ada [15]. Dispensing and
metering of solids is important for many applications but is challenging at milligram scales, though new
strategies are emerging that may decrease the precision required for dosing solid reagents [179]. Indeed,
the set of automatable experiments is ever-increasing, but a universal chemical synthesizer [180] remains
elusive. The result of this gap is that design spaces may be constrained not only through prior knowledge
(an intentional and useful narrowing of the space), but also limited by the capabilities of the automated
hardware available. Characterizing the structure of physical matter is increasingly routine, but our ability to
measure complex functions and connecting those back to structure remains limited. Oliver et al. list several
useful polymer characterization methods that have eluded full automation, such as differential scanning
calorimetry and thermogravimetric analysis [175].
Challenge: Facilitate integration through systems engineering
Scheduling, performing, and analyzing experiments can involve coordinating tasks between several inde-
pendent pieces of hardware/software that must be physically and programmatically linked.
Expanding the scope of experimental platforms may require the integration of independent pieces of
equipment at both the hardware and software level. The wide variety of necessary tasks (scheduling, error-
handling, etc.) means that designing control systems for such highly-integrated platforms is an enormously
complex task [181]. As a result, developing software for integration of an experimental platform [182] (Fig-
ure 2) can be a large contributor to the cost. The lack of a standard API and command set between different
hardware providers means that each requires its own driver and software wrapper; this is particularly true
for analytical equipment, which even lacks standardization in file formats for measured data. Programs like
OVERLORD and Roch et al.’s ChemOS [183] are attempts to create higher-level controllers. Throughput-
matching in sequential workflows is a challenge in general, requiring a plan for “parking” (and perhaps
stabilizing) samples in the event of a bottleneck downstream. These practical issues must be resolved to
benefit from increased integration and the ability to generate data.
Challenge: Automate the planning of multistep chemical syntheses
Many discovery tasks involve proposing new chemical matter; approaching these tasks with autonomous
systems requires the ability to synthesize novel compounds on-demand.
A particularly challenging class of experiments is on-demand synthesis. The primary methodologi-
cal/intellectual challenge for general purpose automated synthesis is the planning of processes–designing
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Figure 2: The workflow of automated synthesis, purification, and testing requires the scheduling of many
independent operations handled by different pieces of hardware and software. Figure reproduced from
Baranczak et al. [182].
multistep synthetic routes using available building blocks; selecting conditions for each reaction step includ-
ing quantities, temperature, and time; and automating intermediate and final purifications. If reduced to
stirring, heating, and fluid transfer operations, chemical syntheses are straightforward to automate [184–
186], and robotic platforms (Figure 3) are capable of executing a series of process steps if those steps are
precisely planned [182, 187]. However, current CASP tools are unable to make directly implementable
recommendations with this level of precision.
There are two diverging philosophies of how to approach automated synthesis: (a) the development of
general-purpose machines able to carry out most chemical reactions, or (b) the development of specialized
machines to perform a few general-purpose reactions that are still able to produce most molecules. The
references in the preceding paragraph follow the former approach. Burke and co-workers have advocated
for the latter and propose using advanced MIDA boronate building blocks and a single reaction/purification
strategy to simplify process design [188]. Peptide and nucleic acid synthesizers exemplify this notion of
automating a small number of chemical transformations to produce candidates within a vast design space.
3.2.2 Computational validation
Many discoveries can be validated with high confidence through computational techniques alone. Where
applicable, this can be extremely advantageous. This is because the logistics of the alternative (physical
experiments) may be much more complex, e.g., relying on access to a large chemical inventory (of candidates
or as precursors) to perform validation experiments within a large design space. An emblematic example
of discoveries that can be validated through computation alone is that of physical matter whose desired
function can be reliably estimated with first principles calculations.
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Figure 3: Rendering of Eli Lilly’s first generation Automated Synthesis Laboratory (ASL) for automated
synthesis and purification. Reproduced from ref. 187.
Challenge: Accelerate code/software used for computational validation
Just as in physical experiments, there are practical challenges in computational experiments related to
the throughput of high fidelity calculations.
A unique feature of computational validation is the well-recognized tradeoff between speed and accuracy.
Consider Lyu et al.’s virtual screen of 170 million compounds to identify binders to two protein targets
through rigid-body docking [189]. The computational pipeline was fast–requiring about one second per
compound–only requiring ≈ 50,000 core-hours in total, and successfully yielded dozens of novel chemotypes
and a few sub-nanomolar binders. While rigid-body docking is not as robust as, say, explicit molecular dy-
namics, its predictions still correlated with experimental binding and generated useful candidate molecules.
An earlier study by Gómez-Bombarelli et al. used time-dependent DFT to evaluate a total of 400,000 candi-
date OLED molecules selected from a pool of 1.6 million enumerated candidates; the computational cost for
this study was roughly 13 million core-hours [11]. There are billions upon billions of molecules in enumerated
synthetically-accessible chemical space. Given our desire to work with broad design spaces, there is a need
for faster workflows that can conduct large-scale computational validation.
One strategy to accelerate computational validation is to create surrogate models of first-principles cal-
culations [11, 14, 190]. Predictions made using surrogate machine learning models regressed to measured
or simulated data almost always carry greater uncertainty than the original experiment, and therefore con-
firming the final discovery is especially reliant on higher-fidelity, often physical validation. An orthogonal
strategy is to accelerate the calculations themselves without sacrificing accuracy. Many computational chem-
20
istry and molecular modeling packages have been developed to take advantage of hardware acceleration on
GPUs [191–193], FPGAs [194], and even ASICs [195].
Challenge: Broaden capabilites / applicability of first-principles calculations
Many properties of interest cannot be simulated accurately, forcing us to rely on experimental validation.
Expanding the scope of what can be accurately modeled would open up additional applications for purely
computational autonomous workflows. There are some tasks for which computational solutions exist but
could be improved, including binding prediction through docking, reactive force field modeling, transition
state searching, conformer generation, solvation energy prediction, and crystal structure prediction. There
are other tasks with even fewer satisfactory approaches, including long timescale molecular dynamics and
multiscale modeling in materials. Some grand challenges in computational chemistry are discussed in refs. 196
and 197.
3.2.3 Shared challenges
Challenge: Ensure that validation reflects the real application
Computational or experimental validation that lends itself to automation is often a proxy for a more
expensive evaluation. If the proxy and the true metric are misaligned, an autonomous platform will not
be able to generate any useful results.
Ideally, there would be perfect alignment between the approaches to validation compatible with an au-
tonomous system and the real task at hand. This is impossible for tasks like drug discovery, where imperfect
in vitro assays are virtually required before evaluating in vivo performance during preclinical development.
For other tasks, assays are simplified for the sake of automation or cost, e.g., Ada’s measurement of optoelec-
tronic properties of a thin film as a proxy for hole mobility as a proxy of the efficiency of a multicomponent
solar cell [15]. Assays used for validation in autonomous systems do not necessarily need to be high through-
put, just high fidelity and automatable. Avoiding false results, especially false negatives in design spaces
where positive hits are sparse such as in the discovery of ligands that bind strongly to a specific protein, is
critical [198].
Challenge: Lower the cost of automated validation
Relatively few things can be automated cheaply. This is especially true for problems requiring complex
experimental procedures, e.g., multi-step chemical synthesis.
While the equipment needed for a basic HTE setup is becoming increasingly accessible and compatible
with the budget of many academic research groups [199, 200], we must increase the complexity of the
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automated platforms that are used for validation in order to increase the complexity of problems that can
be addressed by autonomous workflows. Autonomous systems need not be high-throughput in nature, but,
as we have mentioned several times throughout this review, accelerating search to facilitate exploration
of ever-broader design spaces that we cannot explore manually should be one of the key goals/outcomes of
development of these types of platforms. As the community begins to undertake this challenge, it’s imperative
that we pay attention to affordability, lest we discourage/inhibit adoption. Homegrown systems can be made
inexpensively through integration of common hardware components and open-source languages for control
[185, 201]. Miniaturization reduces material consumption costs, but can complicate system fabrication and
maintenance. The decision to automate a workflow should be the result of a holistic evaluation of return on
investment (ROI) [181].
The costs of computational assays are less of an impediment to autonomous discovery than experimental
assays, given the accessibility of large-scale compute. Improving their accuracy is more of a priority. For
example, the docking method used by Lyu et al. was sufficiently inexpensive to screen millions of com-
pounds and obtain results that correlate with experimental binding affinity, but the majority of high scoring
compounds are false positives and the differentiation of top candidates is poor [189, 202].
Challenge: Combine newly acquired data with prior literature data
Predictive models trained on existing data reflect beliefs about structure-property landscapes; when new
data is acquired, that belief must be updated, preferably in a manner that reflects the relative confidence
of the data sources.
A fundamental question yet to be addressed in studies combining data mining with automated validation
is the following: how should new data acquired through experimental/computational validation be used to
update models pretrained on literature data? The quintessential workflow for non-iterative data-driven dis-
covery of physical matter includes (a) regressing a structure-property dataset, (b) proposing a new molecule,
material, or device, and (c) validating the prediction for a small number of those predictions. Incorporating
this new data into the model should account for the fact that the new data may be generated under more
controlled conditions or may be higher fidelity than the literature data.
The nature of existing data can be different from what is newly acquired. For example, tabulated
reaction data is available at the level of chemical species, temperature, time, intended major product, and
yield. In the lab, we will know the conditions quantitatively (e.g., concentrations, order of addition), will
have the opportunity to record additional factors (e.g., ambient temperature, humidity), and may be able to
measure additional endpoints (e.g., identify side products). However, while we can more thoroughly evaluate
different reaction conditions than what has been previously reported, the diversity of substrates reported in
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the literature exceeds what is practical to have in-stock in any one laboratory; we must figure out how to
meaningfully integrate the two. For discovery tasks that aim to optimize physical matter with standardized
assays, where databases contain exactly what we would calculate or measure, this notion of complementarity
is less applicable.
3.3 Selection of experiments for validation and feedback
Excellent foundational work in statistics on (iterative) optimal experimental design strategies has been
adapted to the domain of chemistry. Although iterative strategies often depend on manually-designed ini-
tializations and constrained search spaces, algorithms can be given the freedom to make decisions about
which hypotheses to test. This flexibility makes iterative strategies inherently more relevant to autonomous
discovery than noniterative ones.
A variety of algorithms exist for efficiently navigating design spaces and/or compound libraries (virtual
or otherwise). Broadly speaking, these can be categorized as model-free–black box optimizations, including
evolutionary algorithms (EAs)–or model-based–using surrogate models for predicting performance and/or
model uncertainty. The latter category includes uncertainty-guided experimental selection where an acqui-
sition function quantifies how useful a new experiment would be [17]; ref. 20 provides a tutorial on Bayesian
optimization.
Challenge: Quantify model uncertainty and domain of applicability
Active learning strategies are crucially dependent on quantifying uncertainty; doing so reliably in
QSAR/QSPR modeling remains elusive, and current strategies cannot anticipate structure-activity cliffs
or other rough features.
Accurate uncertainty quantification drives discovery by drawing attention to underexplored areas of
a design space and helping to triage experiments, e.g., in combination with Bayesian optimization [203].
Statistical and probabilistic frameworks can account for uncertainty when analyzing data and selecting
new experiments [203–207], but we must be able to meaningfully estimate our uncertainty to use them.
Common frequentist methods for estimating uncertainty include model ensembling [208] and Monte Carlo
(MC) dropout [209]; various Bayesian approaches like the use of Gaussian process models have been used
as well [207, 210]. Not only is it difficult to generate meaningful outcomes with these methods, but also
they tend to be computationally expensive (although MC dropout is generally less so than the others). In
QSAR/QSPR, one often tries to define a domain of applicability (DOA) as a coarser version of uncertainty,
where the DOA can be thought of as the input space for which the prediction and uncertainty estimation is
meaningful [211–213].
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There is little to no agreement on the correct way to estimate epistemic uncertainty (as opposed to
aleatoric uncertainty, which is that which arises from measurement noise). In drug discovery, activity cliffs
[214]–sharp changes in binding affinity resulting from minor structural changes–are especially troublesome
and call into question any attempt to directly connect structural similarity to functional similarity [215,
216]. Even functional descriptor-based representations are unlikely to capture all salient features. Implicit or
explicit assumptions must be made when choosing a representational and modeling technique, for example
choosing an appropriate kernel and a prior on (or a hyperparameter controlling) the smoothness of the
landscape in a Gaussian processes model [217].
Challenge: Quantify the tradeoff between experimental difficulty and information gain
Experiment selection criteria should be able to account for the difficulty of an experiment, i.e., employ
cost-sensitive active learning.
Experiment selection methods rarely account for the cost of an experiment in any quantitative way.
Separately, experiment selection is occasionally biased based on factors that are irrelevant to the hypothesis.
If proposed experiments require the synthesis of several molecules (e.g., a compound library designed during
lead optimization), an expert chemist will generally select those they determine to be easily synthesized,
rather than those that are most informative. One must ask if it is worth spending weeks making a single
compound that maximizes the expected improvement or if there is a small analogue library that is easier to
synthesize that, collectively, offers a similar probability of improvement. In this setting, there will almost
always be a tradeoff between data that is fast and inexpensive to acquire and data that is most useful for
the discovery. Understanding that tradeoff is essential for autonomous systems where experiments can have
very different costs (e.g., selecting molecules to be synthesized) or likelihoods of success (e.g., electronic
structure simulations prone to failure) in contrast to where experiments have similar costs (e.g., selecting
virtual molecules for rigid-body docking). The situation becomes more complex for batched optimizations
where, e.g., the cost of synthesizing 96 molecules in a parallel well-plate format is not merely the sum of
their individual costs, but depends on overlap in the precursors and reaction conditions they employ.
Williams et al. provide one example of how to roughly quantify the value of active learning-based screening
for Eve [2]. It is easy to imagine how one might augment this framework to account for cost as part of the
experiment selection process. However, the utility calculation heuristics used by Williams et al. would need
to be substantially improved in order to be usefully applied to cases where the cost of experiments vary,
which is the interesting setting here. To date, the experiments able to be conducted by a given automated
or autonomous workflow are of comparable cost; the decision about whether that cost is reasonable is made
by the human designer of the platform. The term in experimental design for this is cost-sensitive active
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learning [218].
Challenge: Define discovery goals at a higher level
The ability of an automated system to make surprising or significant discoveries relies upon its ability to
extrapolate and explore beyond what is known. This could be encouraged by defining broader objectives
than what is currently done.
In current data analyses, the structure of hypotheses tend to be prescribed: a mathematical function
relating an expert-selected input to an expert-selected output, a correlative measure between two chemical
terms, a causal model that describes a sequence of events. Ideally, we would be able to generate hypotheses
from complex datasets in a more open-ended fashion where do not have to know exactly what we are looking
for. Techniques in knowledge discovery [219], unsupervised learning [220], and novelty detection [221] are
intended for just that purpose and may present a path toward more open-ended generation of scientific
hypotheses (Figure 4).
Figure 4: Overview of the process of knowledge discovery from databases. Figure reproduced from Fayyad
et al. [219].
Experimental design can also be given greater flexibility by defining broad goals for discovery (perfor-
mance, novelty, etc.) and using computational frameworks to learn tradeoffs in reaching those goals, e.g.,
through reinforcement learning. Consider the goal of compound selection during a drug discovery campaign:
to identify a molecule that ends up being suitable for clinical trials. In the earlier information-gathering
stages, we don’t necessarily need to select the highest performing compounds, just the ones that provide
information that lets us eventually identify them (i.e., a future reward). More generally, the experiments
proposed for validation and feedback in a discovery campaign should be selected to achieve a higher-order
goal (eventually, finding the best candidate) rather than a narrow objective (maximizing performance within
a designed compound library).
Open-ended inference is a general challenge in deep learning [222], as is achieving what we would call
creativity in hypothesis generation [223]. At some level, in order to apply optimization strategies for experi-
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mental design or analysis, the goal of a discovery search must be reducible to a scalar objective function. We
should strive to develop techniques for guided extrapolation toward the challenging-to-quantify goals that
the field has used when defining discovery: novelty, interestingness, intelligibility, and utility.
3.3.1 Proposing molecules and materials
Strategies for selecting molecules and materials for validation in discovery workflows are worth additional
discussion (Figure 5). Iterative strategies of the sort described above apply here, with active learning being
useful for selecting compounds from a fixed virtual library and evolutionary/generative algorithms being
useful for designing molecules on-the-fly. Generative models are a particularly attractive way to design
molecules and materials with minimal human input, biased only by knowledge of the chemical space on
which they are trained (Figure 6) [34, 35, 224].
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Figure 5: Common sources of molecules from which to select those that fulfill some design objective.
Molecules can be selected from (a) a fixed, known chemical space, (b) a make-on-demand library of syn-
thesizable compounds, (c) an enumerated library (via systematic enumeration or evolutionary methods),
and (d) molecules proposed de novo from a generative model. *An autoencoder architecture is shown as a
representative type of generative model.
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Figure 6: Schwalbe-Koda and Gómez-Bombarelli’s timeline of generative model development for molecules
(top to bottom). Figure reproduced from ref. 35. Figure subparts reproduced from refs. 225, 226, 227, 228,
229, and 230.
Challenge: Bias generative models towards synthetic accessibility
Compared to fixed virtual libraries, a shortcoming of generative models is that the molecules or materials
they propose may not be easily realizable.
Algorithms that can leverage existing data to suggest promising, as-yet-untested possibilities exist, but
these do not yet function on the level of a human scientist in part because they do not understand what
experiments are possible. Generative models can concoct new molecules in some abstract latent space,
but simplistic measures of synthesizability [231, 232] are not enough to steer the models toward accessible
chemical space. Make-on-demand virtual libraries provide a distinct advantage in that one is more confident
proposed molecule can be made in short timeframe. Achieving that same confidence will be essential for
the adoption of de novo methods, some of which are beginning to combine molecular generation and virtual
enumeration [233]. Some applications of generative models, like to peptide design, do not suffer from this
limitation as, to a first approximation, most peptides are equally synthesizable.
Challenge: Benchmark problems for molecular generative models
The current evaluations for generative models do not reflect the complexity of real discovery problems.
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The explosion of techniques for molecular generation has outpaced our ability to meaningfully assess
their performance. A metric introduced early on as a proxy objective is the “penalized logP” metric for
molecular optimization. While not used for any actual discovery efforts, a heuristic function of estimated
logP, synthetic accessibility, and a penalty for rings larger than 6 atoms was introduced for (and continues
to be used for) benchmarking. This metric bears little resemblance to any multiobjective function one
would use in practice. Only recently have more systematic benchmarks been introduced to cover a wider
range of learning objectives: either maximizing a scalar objective or learning to mimic a distribution of
training molecules. Two frameworks for such model comparisons include GuacaMol [234] and MOSES [235].
However, these do not consider the number of function evaluations required by each method and still represent
simplistic goals. Optimization goals that better reflect the complexity of real discovery tasks might include
binding or selectivity as predicted by docking scores [236]
3.4 Evaluation
Challenge: Demonstrate extrapolative power of predictive models
If the ultimate goal of computer-aided discovery is to generate new scientific knowledge, extrapolation
beyond what is known is a necessity.
The majority of approaches to automated discovery of physical matter rely on predictive models to guide
the selection of experiments. The most effective models to facilitate this process will be able to at least
partially extrapolate from our current knowledge to new chemical matter, eliminating the need for brute force
experimentation. This extrapolative power–the ability of QSAR/QSPR models to generalize to design spaces
they have not been trained on–should be prioritized as an evaluation metrics during model development.
The potential for algorithms to guide us toward novel areas of chemical or reactivity space was emphasized
in a recent review by Gromski et al. [237].
Challenge: Demonstrate design-make-test beyond proof-of-concept
All studies to-date that demonstrate closed-loop design, make, test cycles have been proof-of-concepts
limited to narrow search spaces, severely limiting their practical utility.
A compelling demonstration of autonomous discovery in chemistry would be the closed-loop design,
synthesis, and testing of new molecules to optimize a certain property of interest or build a structure-
property model. There has not been much progress since early proof-of-concept studies that could access only
a limited chemical space [5, 238] despite significant advances in the requisite areas of molecular design, CASP,
and automated synthesis. These constraints on the design space to ensure compatibility with automated
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validation prevent us from addressing many interesting questions and optimization objectives. Chow et al.
describe several case studies where certain steps in the drug discovery have been integrated with each other
for increased efficiency, but acknowledge–as others have–that all stages must be automated and integrated
for maximal efficiency [239–241].
Challenge: Develop benchmark problems for discovery
Developing methods for autonomous discovery would benefit from a “sandbox” that doesn’t eliminate all
of the complexity of real domain applications.
There is no unified strategy for the use of existing data and the acquisition of new data for discovering
functional physical matter, processes, or models. The existence of benchmarks would encourage method
development and makes it easier to evaluate when new techniques are an improvement over existing ones.
We have such evaluations for purely computational problems like numerical optimization and transition state
searching, but there are no realistic benchmarks upon which to test algorithms for autonomous discovery
(e.g., hypothesis generation, experimental selection, etc.).
Vempaty et al. describe one way to evaluate knowledge discovery algorithms through a simplified “coupon-
collector model”; this model assumes that domain knowledge is a set of elements to be identified through
a noisy observation process [242], which represents a limited problem formulation. Even for subtasks with
seemingly better-defined goals like building empirical QSAR/QSPRmodels, there are no standard evaluations
for assessing interpretability, uncertainty quantification, or generalizability. The field will need to collectively
establish a set of problem formulations that describe many discovery tasks of interest to domain experts in
order to benchmark components of autonomous discovery. Given the practical obstacles to validation through
physical experiments, computational chemistry may be the right playground for advancing these techniques.
However, we do caution that an overemphasis on quantitative benchmarking can be detrimental. Lan-
guage tasks have reached a point where the amount of compute required for competitive performance is
inaccessible for all but the most well-resourced research groups [243]. Unless benchmarking controls what
(open source) training data is permissible, a lack of access to compute and data may inadvertently discourage
method development.
4 Conclusion
4.1 Attribution of discovery to automation
The case studies in this article illustrate that computer assistance and automation have become ubiquitous
parts of scientific discovery both by reducing the manual effort required to complete certain tasks and by
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enabling entirely new approaches to discovery at an unprecedented throughput. But to what extent can the
discovery itself be considered a direct result of automation or autonomy?
As summarized in our reflection of the case studies in Part 1, very few studies can claim to have achieved a
high level of autonomy. In particular, researchers frequently gloss over the fact that specifying the discovery
objective, defining the search space, and narrowing that space to the “relevant” space that is ultimately
explored requires substantial manual input. While there will always be a need for subject matter experts
in constructing these platforms and associated workflows, we hope it will be possible to endow autonomous
platforms with sufficiently broad background knowledge and validation capabilities that this initial narrowing
of the search space is less critical to their success.
4.2 Changing definitions of discovery
The bar for what makes a noteworthy discovery is ever-increasing. Computer-aided structural elucidation,
building structure-activity relationships, and automated reaction optimization are all discoveries under the
definition we have presented here, but they are not perceived to be as significant as they were in the past.
As computational algorithms become more flexible and adaptive in other contexts, and as the scope of
automatable validation experiments expands, more and more workflows will appear routine.
We have intentionally avoided a precise definition of the degree of confidence required for a discovery
without direct experimental observation of a desired physical property. This is because this varies widely
by domain and is rapidly evolving as computational validation techniques and proxy assays become more
accurate. A computational prediction of a new chemical reaction would likely not be considered a discovery
under any circumstances without experimental validation. A computational prediction of a set of bioactive
compounds might, but with a subjective threshold for the precision of its recommendations. Whether the
computational workflow has directly made the discovery of a new compound might depend if all of the top
n compounds were found to be active, or if at least m of the top n were, etc.
4.3 Role of the human
The current role of humans in computer-assisted discovery is clear. Langley writes of the “developer’s role”
in terms of high-level tasks: formulating the discovery problem, settling on an effective representation, and
transforming the output into results meaningful to the community [244, 245]. Honavar includes mapping the
current state of knowledge and generating/prioritizing research questions [246].
Alan Turing’s imitation game (“the Turing test”) asks whether a computer program can be made indis-
tinguishable from a human conversationalist [247]. It is interesting to wonder if we can reach a point where
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autonomous platforms are able to report insights and interpretations that are indistinguishable (both in
presentation and scientific merit) from what a human researcher might publish in a journal article. Among
other things, this would require substantial advances in hypothesis generation, explainability, and scientific
text generation. Machine-generated review articles and textbooks may be the first to pass this test [248].
Kitano’s more ambitious grand challenge in his call-to-arms is to make a discovery in the biomedical sciences
worthy of a Nobel Prize [170].
We do not want to overstress a direct analogy of the Turing test to autonomous discoveries, because the
type of discoveries typically enabled by automation and computational techniques are often distinct from
those made by hand. For the field to have the broadest shared capabilities, the best discovery platforms
will excel at tasks that humans can’t easily or safely do. The scale of data generation, the size of a design
space that can be searched, and the ability to define new experiments that account for enormous quantities
of existing information makes autonomous systems equipped to make discoveries in ways entirely distinct
from humans.
Turing makes the point that the goals of machines and programs are distinct; that a human would lose in
a race with an airplane does not mean we should slow down airplanes so their speeds are indistinguishable.
Rephrased more recently by Steve Ley, “while people are always more important than machines, increasingly
we think that it is foolish to do thing machines can do better than ourselves” [249]. Particularly when faced
with the grunt work of some manual experimentation, “leaving such things to machines frees us for still
better tasks” (Derek Lowe) [180]. We should embrace the divergence of human versus machine tasks.
4.4 Outlook
We join many others in touting the promise of autonomous or accelerated discovery [239, 241, 250–258].
Automation has brought increased productivity to the chemical sciences through efficiency, reproducibility,
reduction in error, and the ability to cope with complex problems at scale; likewise, machine learning and
data science through the identification of highly nonlinear relationships, trends, and patterns in complex
data.
The previous section identified a number of directions in which additional effort is required to capture the
full value of that promise: creating and maintaining high-quality open access datasets; building interpretable,
data-efficient, and generalizable empirical models; expanding the scope of automated experimental platforms,
particularly for multistep chemical synthesis; improving the applicability and speed of automated compu-
tational validation; aligning automated validation with prior knowledge and what is needed for different
discovery applications, ideally not at significant cost; improving uncertainty quantification and cost-sensitive
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active learning; enabling open-ended hypothesis generation for experimental selection; and explicitly incorpo-
rating synthesizability considerations into generative models and benchmarking on realistic tasks. Evaluation
will require the creation of benchmark problems that we argue should focus on whether algorithms facilitate
extrapolation to underexplored, large design spaces that are currently expensive or intractable to explore.
Numerous research initiatives are supporting work in these directions. For example, the United States
Department of Defense recently funded a multidisciplinary initiative to develop a Scientific Autonomous
Reasoning Agent; the Defense Advanced Research Projects Agency (DARPA) has funded several programs
relevant to autonomous discovery, including the Data-Driven Discovery of Models, Big Mechanism Project,
Make-It, Accelerated Molecular Discovery, and Synergistic Discovery and Design; the Engineering and Physi-
cal Sciences Research Council (EPSRC) has an ongoing Dial-a-Molecule challenge that strives to debottleneck
synthesis, and recently launched a Centre of Doctoral Training in Automated Chemical Synthesis enabled
by Digital Molecular Technologies; the Materials Genome Initiative, Materials Project, and Mission Innova-
tion’s Materials Acceleration Platform continue to bring sweeping changes to how data is materials science
is collected, curated, and applied to discovery. Many more commercial efforts are underway as well, with
significant investment from the pharmaceutical industry into the integration and digitization of their drug
discovery workflows.
A 2004 perspective article by Glymour stated that we were in the midst of a revolution to automate
scientific discovery [259]. Regardless of whether we were then, we certainly seem to be now.
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